{"id":"prevnar13","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site erythema"},{"rate":"15-30","effect":"Injection site swelling"},{"rate":"10-25","effect":"Injection site pain"},{"rate":"10-15","effect":"Fever"},{"rate":"5-10","effect":"Irritability"},{"rate":"5-10","effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsules from 13 serotypes of pneumococcus conjugated to a carrier protein, which enhances immunogenicity and promotes T-cell dependent immune responses. This triggers both humoral and cellular immunity, enabling the body to recognize and eliminate pneumococcal bacteria before infection becomes severe. The vaccine is used for prevention of pneumococcal disease across multiple age groups.","oneSentence":"Prevnar 13 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:36.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in infants and children (2 months to 5 years)"},{"name":"Prevention of invasive pneumococcal disease in adults aged 50 years and older"},{"name":"Prevention of pneumococcal otitis media and pneumonia in pediatric populations"}]},"trialDetails":[{"nctId":"NCT07017777","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-11-14","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":600},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT04745559","phase":"PHASE2","title":"Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-02-18","conditions":"Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)","enrollment":26},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT06617715","phase":"PHASE3","title":"Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-10-23","conditions":"Pneumococcal Infectious Disease","enrollment":3080},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT05412030","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-06-16","conditions":"Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":388},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT04583618","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-10-08","conditions":"Pneumococcal Immunization","enrollment":750},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT03859687","phase":"PHASE1","title":"Trial of Antibody Responses by Vitamin Supplementation","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-19","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT03376477","phase":"PHASE2","title":"Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-09-23","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT03104075","phase":"PHASE4","title":"Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines","status":"COMPLETED","sponsor":"The Jackson Laboratory","startDate":"2017-04-17","conditions":"Pneumonia, Aging","enrollment":40},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT03819049","phase":"PHASE1, PHASE2","title":"A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-06","conditions":"Extraintestinal Pathogenic Escherichia Coli Prevention","enrollment":836},{"nctId":"NCT03035331","phase":"PHASE1, PHASE2","title":"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-08-15","conditions":"Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":11},{"nctId":"NCT01527591","phase":"NA","title":"Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2012-02-01","conditions":"Infection in Solid Organ Transplant Recipients","enrollment":17},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT06698198","phase":"PHASE1","title":"Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-03","conditions":"Pneumococcal Immunization","enrollment":175},{"nctId":"NCT03489018","phase":"PHASE4","title":"The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-03-21","conditions":"Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against","enrollment":2100},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT04633226","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-10","conditions":"Pneumococcal Disease","enrollment":58},{"nctId":"NCT04275284","phase":"","title":"Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-02-14","conditions":"Pneumonia, Meningitis","enrollment":600},{"nctId":"NCT03729778","phase":"EARLY_PHASE1","title":"Impact of HIV-1 and Aging on Mucosal Vaccine Responses","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Eastern Colorado Health Care System","startDate":"2017-01-18","conditions":"HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS","enrollment":100},{"nctId":"NCT03384589","phase":"PHASE2, PHASE3","title":"CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2018-08-23","conditions":"Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection","enrollment":248},{"nctId":"NCT06202703","phase":"NA","title":"Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-04-15","conditions":"Vaccine-Preventable Diseases","enrollment":5},{"nctId":"NCT03803202","phase":"PHASE1, PHASE2","title":"A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-01-24","conditions":"Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease","enrollment":630},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03565900","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Pneumococcal Infections","enrollment":277},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT03692871","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-14","conditions":"Pneumococcal Infections","enrollment":2409},{"nctId":"NCT04384107","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-01","conditions":"Pneumococcal Infections","enrollment":694},{"nctId":"NCT03921424","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Pneumococcal Infections","enrollment":407},{"nctId":"NCT01272999","phase":"","title":"Impact of Prevnar 13 on Ear Infections in Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-05-21","conditions":"Acute Otitis Media, Mastoiditis","enrollment":391},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT03885934","phase":"PHASE3","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-25","conditions":"Pneumococcal Infections","enrollment":606},{"nctId":"NCT05602480","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2022-11-01","conditions":"Pneumococcal Infections","enrollment":264},{"nctId":"NCT02851056","phase":"EARLY_PHASE1","title":"Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-09-27","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT02716805","phase":"PHASE1","title":"Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant","status":"TERMINATED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-12-13","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT01953510","phase":"PHASE2, PHASE3","title":"Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2013-09-30","conditions":"Pneumococcal Vaccines","enrollment":1400},{"nctId":"NCT03619252","phase":"PHASE4","title":"Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents","status":"COMPLETED","sponsor":"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","startDate":"2018-07-01","conditions":"Multiple Myeloma, Pneumococcal Infection, Febrile Neutropenia","enrollment":36},{"nctId":"NCT02049138","phase":"PHASE2","title":"An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01-24","conditions":"Rheumatoid Arthritis","enrollment":493},{"nctId":"NCT04978038","phase":"PHASE4","title":"Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs","status":"UNKNOWN","sponsor":"Mark Loeb","startDate":"2022-08-01","conditions":"SARS-CoV2 Infection, Coronavirus Infection","enrollment":414},{"nctId":"NCT04525599","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator","status":"COMPLETED","sponsor":"Affinivax, Inc.","startDate":"2020-09-22","conditions":"Healthy Volunteers, Pneumococcal Disease","enrollment":75},{"nctId":"NCT03480802","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-06","conditions":"Pneumococcal Infections","enrollment":302},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT05145101","phase":"","title":"Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia","status":"UNKNOWN","sponsor":"Hannah Garcia Garrido","startDate":"2020-05-07","conditions":"Pneumococcal Infections, Chronic Lymphocytic Leukemia, Vaccine-Preventable Diseases","enrollment":150},{"nctId":"NCT03550313","phase":"PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-06-01","conditions":"Pneumococcal Infections","enrollment":565},{"nctId":"NCT02225587","phase":"PHASE3","title":"Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-28","conditions":"Pneumococcal Infections","enrollment":400},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652},{"nctId":"NCT02370069","phase":"PHASE4","title":"The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13","status":"COMPLETED","sponsor":"Lakehead University","startDate":"2015-06","conditions":"Chronic Kidney Diseases","enrollment":138},{"nctId":"NCT03731182","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-23","conditions":"Pneumococcal Infections","enrollment":104},{"nctId":"NCT03802994","phase":"EARLY_PHASE1","title":"Pneumococcal Conjugate Vaccine in Aging Renal Transplant","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-11-01","conditions":"Renal Transplantation, Aging","enrollment":57},{"nctId":"NCT03950622","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-13","conditions":"Pneumococcal Infections","enrollment":1205},{"nctId":"NCT03950856","phase":"PHASE3","title":"Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-12","conditions":"Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":2340},{"nctId":"NCT01641133","phase":"PHASE3","title":"Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-04","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":457},{"nctId":"NCT02309515","phase":"PHASE2","title":"Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-06-11","conditions":"Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT03547167","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-16","conditions":"Pneumococcal Infections","enrollment":1515},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT03039491","phase":"EARLY_PHASE1","title":"Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2015-09-01","conditions":"HIV Lipodystrophy, Aging","enrollment":160},{"nctId":"NCT02494999","phase":"PHASE3","title":"A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-06","conditions":"Pneumonia","enrollment":1200},{"nctId":"NCT02201030","phase":"PHASE3","title":"Immunogenicity and Safety Study of NBP606 in Healthy Infants","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-09-06","conditions":"Pneumococcal Infections","enrollment":577},{"nctId":"NCT02927444","phase":"PHASE3","title":"Immunogenicity and Safety Study of NBP606 in Healthy Toddlers","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2015-11-04","conditions":"Pneumococcal Infections","enrollment":462},{"nctId":"NCT01735084","phase":"PHASE4","title":"Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2013-03-12","conditions":"Otitis Media, Febrile Illness, Cough","enrollment":261},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT01545375","phase":"PHASE2","title":"Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-21","conditions":"Infections, Streptococcal","enrollment":1806},{"nctId":"NCT03313037","phase":"PHASE2","title":"Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-10-10","conditions":"Pneumococcal Infections","enrollment":444},{"nctId":"NCT04183322","phase":"","title":"PCV13 in Non-pregnant Papua New Guinean Women","status":"COMPLETED","sponsor":"Telethon Kids Institute","startDate":"2016-05-10","conditions":"Pneumococcal Infections","enrollment":50},{"nctId":"NCT02096263","phase":"PHASE3","title":"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-16","conditions":"Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b","enrollment":585},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT02987972","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-21","conditions":"Pneumococcal Infections","enrollment":1051},{"nctId":"NCT03467984","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2018-05-25","conditions":"Pneumococcal Infection","enrollment":230},{"nctId":"NCT02573181","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-30","conditions":"Pneumococcal Infections","enrollment":253},{"nctId":"NCT01616459","phase":"PHASE2","title":"Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-11","conditions":"Infections, Streptococcal","enrollment":953},{"nctId":"NCT02422264","phase":"PHASE4","title":"Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-22","conditions":"Acellular Pertussis, Tetanus, Poliomyelitis","enrollment":601},{"nctId":"NCT02037984","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01-28","conditions":"Streptococcus Pneumoniae Infection, Pneumococcal Infections","enrollment":341},{"nctId":"NCT01262872","phase":"PHASE2","title":"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-09","conditions":"Infections, Streptococcal","enrollment":1320},{"nctId":"NCT03642847","phase":"PHASE1","title":"Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-08-29","conditions":"Pneumococcal Infections","enrollment":104},{"nctId":"NCT01282216","phase":"PHASE2","title":"Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2011-04","conditions":"Transplant-Related Cancer","enrollment":120},{"nctId":"NCT01204658","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-27","conditions":"Infections, Streptococcal","enrollment":576},{"nctId":"NCT01215188","phase":"PHASE2","title":"A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-14","conditions":"Pneumococcal Infections","enrollment":1152},{"nctId":"NCT02547649","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-08","conditions":"Pneumococcal Infections","enrollment":690},{"nctId":"NCT02531373","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-15","conditions":"Pneumococcal Infections","enrollment":338},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01349569","phase":"PHASE2","title":"Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-01","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT01513551","phase":"PHASE2","title":"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-03-13","conditions":"Pneumococcal Infections","enrollment":692},{"nctId":"NCT01128439","phase":"","title":"Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Invasive Pneumococcal Disease","enrollment":1}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ABDOMINAL DISCOMFORT"},{"count":2,"reaction":"AGITATION"},{"count":2,"reaction":"DIZZINESS"},{"count":2,"reaction":"DRY MOUTH"},{"count":2,"reaction":"HEAD INJURY"},{"count":2,"reaction":"HEADACHE"},{"count":2,"reaction":"MICTURITION URGENCY"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"OROPHARYNGEAL PAIN"},{"count":2,"reaction":"SOMNOLENCE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pneumococcal Vaccine","pneumococcal vaccine","13- valent conjugate pneumococcal vaccine","PCV13","Pneumovax23"],"phase":"marketed","status":"active","brandName":"Prevnar13","genericName":"Prevnar13","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prevnar 13 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in infants and children (2 months to 5 years), Prevention of invasive pneumococcal disease in adults aged 50 years and older, Prevention of pneumococcal otitis media and pneumonia in pediatric populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":9,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}